DRMA Stock Price, Dermata Therapeutics, Quote, Chart

Market Summary

USD0.35+0.01

Market Closed

2.94%

DRMA Stock Price

View Fullscreen

DRMA RSI Chart

DRMA Valuation

Market Cap

2.3M

Price/Earnings (Trailing)

-0.3

Price/Sales (Trailing)

9.43

Price/Free Cashflow

-0.36

DRMA Price/Sales (Trailing)

DRMA Profitability

Return on Equity

-122.65%

Return on Assets

-97.69%

Free Cashflow Yield

-274.91%

DRMA Fundamentals

DRMA Revenue

Revenue (TTM)

247.2K

DRMA Earnings

Earnings (TTM)

-7.8M

Earnings Growth (Yr)

-27.81%

Earnings Growth (Qtr)

-24.13%

Breaking Down DRMA Revenue

Last 7 days

9.4%

Last 30 days

-10.3%

Last 90 days

-32.7%

Trailing 12 Months

-79.8%

How does DRMA drawdown profile look like?

DRMA Financial Health

Current Ratio

7.66

DRMA Investor Care

Shares Dilution (1Y)

321.61%

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2023	0	0	0	247.2K
2022	0	0	0	63.6K

Get all data in R, Python etc through our Historical Stock Data APIs

Tracking the Latest Insider Buys and Sells of Dermata Therapeutics, Inc

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Oct 06, 2022	bradrick brittany	acquired	-	-	9,810	-
Oct 06, 2022	scott kathleen d.	acquired	-	-	11,359	-
Oct 06, 2022	sandler andrew seth	acquired	-	-	10,120	-
Oct 06, 2022	fisher mary	acquired	-	-	9,810	-
Oct 06, 2022	wierenga wendell	acquired	-	-	20,654	-
Oct 06, 2022	hale david f	acquired	-	-	30,155	-
Jul 07, 2022	sandler andrew seth	acquired	-	-	8,874	-
Jul 07, 2022	hale david f	acquired	-	-	26,441	-
Jul 07, 2022	wierenga wendell	acquired	-	-	18,110	-
Jul 07, 2022	fisher mary	acquired	-	-	8,602	-

Which funds bought or sold DRMA recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
Feb 26, 2024	Virtu Financial LLC	new	-	8,000	8,000	-%
Feb 14, 2024	TWO SIGMA SECURITIES, LLC	sold off	-100	-11,752	-	-%
Feb 14, 2024	BOOTHBAY FUND MANAGEMENT, LLC	unchanged	-	-5,400	7,320	-%
Feb 13, 2024	GEODE CAPITAL MANAGEMENT, LLC	unchanged	-	-5,507	7,464	-%
Feb 13, 2024	Tower Research Capital LLC (TRC)	added	24.85	-1,535	3,916	-%
Feb 13, 2024	ARMISTICE CAPITAL, LLC	new	-	132,980	132,980	-%
Feb 13, 2024	ARMISTICE CAPITAL, LLC	added	1,499	-213	142	-%
Feb 13, 2024	ACADIAN ASSET MANAGEMENT LLC	reduced	-26.95	-47,000	32,000	-%
Feb 09, 2024	UBS Group AG	reduced	-40.23	-78.00	23.00	-%
Feb 09, 2024	UBS Group AG	sold off	-100	-139	-	-%

Are Funds Buying or Selling DRMA?

Are funds buying DRMA calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own DRMA

No. of Funds

Unveiling Dermata Therapeutics, Inc's Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Feb 14, 2024	armistice capital, llc	9.99%	412,111	SC 13G
Jun 01, 2023	intracoastal capital, llc	4.99%	143,944	SC 13G
Mar 31, 2023	hale david f	1.9%	44,833	SC 13D/A
Mar 30, 2023	proehl gerald t	9.6%	233,030	SC 13D/A
Jan 18, 2023	proehl gerald t	28.9%	3,721,035	SC 13D/A
May 05, 2022	proehl gerald t	37.7%	3,658,445	SC 13D/A

Recent SEC filings of Dermata Therapeutics, Inc

View All Filings

Date Filed	Form Type	Document
Mar 26, 2024	DEFA14A	DEFA14A
Mar 26, 2024	DEF 14A	DEF 14A
Mar 26, 2024	ARS	ARS
Mar 21, 2024	8-K	Current Report
Mar 21, 2024	10-K	Annual Report
Mar 04, 2024	PRE 14A	PRE 14A
Feb 14, 2024	SC 13G	Major Ownership Report

Peers (Alternatives to Dermata Therapeutics, Inc)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
MRNA	41.2B	6.8B	-2.42%	-17.04%	-8.75	6.02	-64.45%	-156.37%
HILS	22.4B	152.6K	-0.77%	465779.94%	-2.4K	146.8K	-	-9.98%
ALNY	18.0B	1.8B	-7.18%	-26.90%	-41	9.87	76.23%	61.08%
BMRN	15.4B	2.5B	-8.70%	-12.49%	74.73	6.21	13.74%	186.89%
INCY	11.6B	3.7B	-9.54%	-29.84%	19.41	3.14	8.87%	75.42%
MID-CAP
APLS	6.0B	396.6M	-14.77%	-39.78%	-11.37	15.16	425.83%	18.94%
BBIO	4.4B	-	-19.35%	75.41%	-6.7	60.35	54.84%	-34.79%
AXSM	3.4B	270.6M	-9.32%	0.89%	-14.22	12.57	440.80%	-27.84%
ACAD	2.8B	726.4M	-8.24%	-18.54%	-44.9	3.79	40.45%	71.62%
ARWR	2.7B	240.7M	-22.93%	-36.73%	-9.23	12.18	-1.03%	-92.09%
SMALL-CAP
CPRX	1.8B	398.2M	-8.48%	-5.52%	24.58	4.41	85.90%	-14.05%
NVAX	569.6M	983.7M	-16.08%	-46.16%	-1.05	0.58	-50.36%	17.16%
CRBP	361.2M	881.7K	-3.23%	346.43%	-8.1	466.16	-77.61%	-5.33%
INO	247.0M	4.9M	-18.88%	12.93%	-1.83	50.76	-54.97%	51.71%
IBIO	6.1M	2.1M	-47.62%	62.96%	-0.22	2.14	-13.45%	66.37%

Dermata Therapeutics, Inc News

Latest updates

Dermata Therapeutics, Inc Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Income Statement (Quarterly)		(In Thousands)
Description	(%) Q/Q	2023Q4	2022Q4
Operating Expenses	29.7%	2,220	1,712
S&GA Expenses	31.9%	1,085	822
R&D Expenses	27.6%	1,135	889
Interest Expenses	-100.0%	-	42.00
Income Taxes	-100.0%	-	150*
Net Income	-27.8%	-2,133	-1,669
Net Income Margin	-Infinity%	-31.53*	-
Free Cashflow	37.2%	-1,147	-1,825

Balance Sheet

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Balance Sheet														(In Thousands)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2019Q4
Assets	8.9%	7,979	7,323	8,713	9,295	6,944	8,975	11,026	9,044	11,624	13,686	1,137	871	605	2,066
Current Assets	-	-	-	-	-	-	-	-	-	11,624	13,686	1,137	-	605	2,065
Cash Equivalents	12.2%	7,438	6,631	8,439	8,767	6,241	8,067	10,628	8,191	10,799	12,603	427	1,330	530	1,992
Net PPE	-	-	-	-	-	-	-	-	-	-	-	-	-	-	322*
Liabilities	77.1%	1,624	917	683	1,207	923	1,504	1,366	1,191	1,517	1,195	1,643	2,713	3,783	2,276
Current Liabilities	-	-	-	-	-	-	-	-	-	1,517	1,195	1,643	-	3,783	1,723
LT Debt, Current	-	-	-	-	-	-	-	-	-	-	-	-	-	556	731
Shareholder's Equity	-0.8%	6,355	6,407	8,030	8,088	6,022	7,471	9,660	7,853	10,107	12,491	-	712	-	-
Retained Earnings	-4.2%	-53,387	-51,253	-49,534	-47,833	-45,593	-43,923	-41,499	-38,768	-35,982	-33,429	-31,716	-	-28,079	-24,843
Additional Paid-In Capital	3.6%	59,743	57,660	57,564	55,921	51,615	51,393	51,158	46,620	46,089	45,919	31,203	-	-	-
Shares Outstanding	23.3%	3,931	3,189	3,189	2,388	770	756	631	521	521	521	119	-	119	119
Float	-	-	-	4,800	-	-	-	4,000	-	-	-	-	-	-	-

Cashflow (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Cashflow (Quarterly)																(In Thousands)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2019Q4
Cashflow From Operations	35.2%	-1,147	-1,771	-1,840	-1,649	-1,825	-2,561	-1,839	-2,607	-1,803	-2,210	-903	-776	-535	-1,369	-	-
Share Based Compensation	-2.1%	128	131	131	131	221	235	262	213	489	143	994	280	-	-	-	-
Cashflow From Financing	5616.7%	1,954	-35.42	1,512	4,175	-	200*	4,276	-	-626*	14,386	-	1,576	313	1,386	-	-

DRMA Income Statement

2023-12-31

Statements of Operations - USD ($)	12 Months Ended
Statements of Operations - USD ($)	Dec. 31, 2023	Dec. 31, 2022
Operating expenses:
Research and development	$ 4,069,766	$ 5,651,041
General and administrative	3,972,140	4,023,445
Total operating expenses	8,041,906	9,674,486
Loss from operations	(8,041,906)	(9,674,486)
Other income and expenses:
Interest income, net	(247,216)	(63,573)
Net loss	$ (7,794,690)	$ (9,610,913)
Net loss per share of common stock, basic and diluted	$ (2.67)	$ (13.92)
Weighted-average basic and diluted common shares	2,924,398	690,666

DRMA Balance Sheet

2023-12-31

Balance Sheets - USD ($)	Dec. 31, 2023	Dec. 31, 2022
Assets:
Cash and cash equivalents	$ 7,438,135	$ 6,241,294
Prepaid expenses and other current assets	540,499	703,194
Total assets	7,978,634	6,944,488
Liabilities:
Accounts payable	866,028	496,702
Accrued and other current liabilities	757,588	425,932
Total liabilities	1,623,616	922,634
Stockholders' Equity:
Common Stock, par value $0.0001, 250,000,000 shares authorized as of December 31, 2023, and 2022; 3,931,129 and 770,115 shares issued and outstanding as of December 31, 2023, and 2022, respectively.	393	77
Additional paid-in capital	59,742,503	51,614,965
Accumulated deficit	(53,387,878)	(45,593,188)
Total stockholders' equity	6,355,018	6,021,854
Total liabilities and stockholders' equity	$ 7,978,634	$ 6,944,488

About Dermata Therapeutics, Inc

Dermata Therapeutics, Inc., a clinical-stage medical dermatology company, focuses on identifying, developing, and commercializing pharmaceutical product candidates for the treatment of medical and aesthetic skin conditions and diseases. The company's lead product candidate is DMT310, which has completed Phase IIb clinical trial for treatment of moderate-to-severe acne; and Phase Ib proof of concept (POC) trial for Mild-to-Moderate Psoriasis, as well as is in a Phase 2 clinical trial for treatment of moderate-to-severe rosacea. It is also developing DMT410 that has completed Phase Ib POC trials for the treatment of anxillary hyperhidrosis and aesthetic conditions. Dermata Therapeutics, Inc. was incorporated in 2014 and is headquartered in San Diego, California.

CEO	Mr. Gerald T. Proehl
WEBSITE	dermatarx.com
INDUSTRY	Biotechnology
EMPLOYEES	8

Dermata Therapeutics, Inc Frequently Asked Questions

What is the ticker symbol for Dermata Therapeutics, Inc? What does DRMA stand for in stocks?

DRMA is the stock ticker symbol of Dermata Therapeutics, Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Dermata Therapeutics, Inc (DRMA)?

As of Fri Apr 26 2024, market cap of Dermata Therapeutics, Inc is 2.33 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of DRMA stock?

You can check DRMA's fair value in chart for subscribers.

What is the fair value of DRMA stock?

You can check DRMA's fair value in chart for subscribers. The fair value of Dermata Therapeutics, Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Dermata Therapeutics, Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for DRMA so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Dermata Therapeutics, Inc a good stock to buy?

The fair value guage provides a quick view whether DRMA is over valued or under valued. Whether Dermata Therapeutics, Inc is cheap or expensive depends on the assumptions which impact Dermata Therapeutics, Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for DRMA.

What is Dermata Therapeutics, Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Fri Apr 26 2024, DRMA's PE ratio (Price to Earnings) is -0.3 and Price to Sales (PS) ratio is 9.43. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. DRMA PE ratio will change depending on the future growth rate expectations of investors.